Ashkon Software



IMMY - Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. logo Imprimis Pharmaceuticals, Inc. (IMMY) is a specialty pharmaceutical company focused on developing, manufacturing, and selling novel and customized compounded drug formulations. The company’s product portfolio includes compounded drugs for ophthalmology, urology, pain management, and other therapeutic areas.

One of the company’s most notable products is its compounded formulation of pyrimethamine and leucovorin, which is used to treat toxoplasmosis, a parasitic infection that can cause blindness and other serious health problems. This formulation gained attention in 2015 when Turing Pharmaceuticals, under the leadership of Martin Shkreli, raised the price of the only FDA-approved pyrimethamine drug from $13.50 to $750 per tablet. Imprimis responded by creating a more affordable compounded version of the drug, which sparked controversy and highlighted the issue of high drug prices in the U.S.

In addition to its compounded drug formulations, Imprimis also has a drug development pipeline focused on oncology and ophthalmology. The company is developing a proprietary drug delivery technology platform, known as Accudel, which is designed to enhance the effectiveness and safety of injectable drugs.

Imprimis Pharmaceuticals was founded in 1998 and is headquartered in San Diego, California. The company’s stock is traded on the Nasdaq Global Market under the ticker sym




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer